Literature DB >> 2672418

Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

L M Sayre1.   

Abstract

The various biochemical mechanisms considered to explain the selective dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are reviewed. MPTP is metabolized by monoamine oxidase in the brain, ultimately yielding 1-methyl-4-phenylpyridinium cation (MPP+), which is accumulated in dopamine cells by the high-affinity dopamine uptake pump. Cell death appears to reflect a compromise in energy production arising as a result of the Nernstian concentration of MPP+ inside mitochondria and persistent inhibition of Site 1 of the respiratory chain. The structural features underlying each biochemical step involved in the expression of neurotoxicity are described, and the implications of the MPTP phenomenon to efforts aimed at elucidating the pathogenesis of idiopathic parkinsonism are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2672418     DOI: 10.1016/0378-4274(89)90168-9

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  15 in total

1.  Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Authors:  Rosa Canet-Aviles; Geoffrey P Lomax; Ellen G Feigal; Catherine Priest
Journal:  Stem Cells Transl Med       Date:  2014-08-22       Impact factor: 6.940

2.  Neurotrophic Effect of Asiatic acid, a Triterpene of Centella asiatica Against Chronic 1-Methyl 4-Phenyl 1, 2, 3, 6-Tetrahydropyridine Hydrochloride/Probenecid Mouse Model of Parkinson's disease: The Role of MAPK, PI3K-Akt-GSK3β and mTOR Signalling Pathways.

Authors:  Jagatheesan Nataraj; Thamilarasan Manivasagam; Arokiasamy Justin Thenmozhi; Musthafa Mohamed Essa
Journal:  Neurochem Res       Date:  2017-02-08       Impact factor: 3.996

3.  Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: lack of correlation with superoxide generation.

Authors:  Brian P Dranka; Jacek Zielonka; Anumantha G Kanthasamy; Balaraman Kalyanaraman
Journal:  J Neurochem       Date:  2012-07-11       Impact factor: 5.372

4.  Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice.

Authors:  R Zwart; S Verhaagh; M Buitelaar; C Popp-Snijders; D P Barlow
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

5.  Disruption of lateral olivocochlear neurons via a dopaminergic neurotoxin depresses sound-evoked auditory nerve activity.

Authors:  Colleen G Le Prell; Kärin Halsey; Larry F Hughes; David F Dolan; Sanford C Bledsoe
Journal:  J Assoc Res Otolaryngol       Date:  2005-04-22

Review 6.  Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?

Authors:  A Barzilai; E Melamed; A Shirvan
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

7.  Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine.

Authors:  R Albores; E J Neafsey; G Drucker; J Z Fields; M A Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

8.  Modulation of MPP+ uptake by tea and some of its components in Caco-2 cells.

Authors:  R Monteiro; C Calhau; F Martel; A Faria; N Mateus; I Azevedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-22       Impact factor: 3.000

9.  Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission.

Authors:  Paul J Gasser; Christopher A Lowry; Miles Orchinik
Journal:  J Neurosci       Date:  2006-08-23       Impact factor: 6.167

10.  Abnormal muscle and skin mitochondria in family with myoclonus, ataxia, and deafness (May and White syndrome).

Authors:  J Vaamonde; J Muruzabal; T Tuñón; N Perez; J Artieda; M Rodriguez; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.